EPI ONE
OperatingEpi One Inc.
Healthcare · Brooklyn, NY · Founded 2016
Accurate, Affordable early cancer detection
Financials
FY2022–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines, and each class is drawn as its own line.
Cap table
Share counts as of Dec 31, 2025| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Class A Common Stock | 5,338,984 | — | 100.0% | $0.015Jun 2023 |
Sold to the crowd
- Reg CF · May 2024151,192 shares at $7.28$1.1M· 205 investors
- Reg CF · Sep 2024258,828 shares at $7.28$1.9M· 458 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
4 people
Neng, one of Epi One’s co-founders, adept in next-gen sequencing and CAR T-cell therapy, drives biomarker validation. Formerly at Sloan Kettering, she pioneered single-cell sorting for leukemia and researched CAR T-cell therapy for lung cancer. She holds an MD from Guangdong and, Ph.D. from Shanghai JiaoTong.
Sophia, with both an MD and Ph.D., leverages research expertise from Memorial Sloan Kettering to lead scientific strategy at Epi One. Her focus on genomics and cancer biology drives clinical success. She holds degrees from Harbin Medical University and Iowa State University.
Daniel, Co-Founder of RethinkFirst, boasts three decades of global business experience. A serial entrepreneur with expertise in healthcare, tech, and strategy, he has scaled multiple businesses to successful exits and holds degrees from Yale University and Harvard Business School.
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 2 of 2 annual reports (FY2024–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
- Form C-AR/AApr 29, 20260002018216-26-000008EDGAR
- Form C-ARApr 28, 20260002018216-26-000007EDGAR
- Form C-ARApr 28, 20260002018216-26-000006EDGAR
- Form C-USep 25, 20240001665160-24-001347EDGAR
- Form CSep 5, 20240001665160-24-001287EDGAR
- Form C/AAug 26, 20240001665160-24-001229EDGAR
- Form C/AAug 14, 20240001665160-24-001177EDGAR
- Form CMay 20, 20240001665160-24-000877EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.